MentionFox
Home › Executive changes › Semnur Pharmaceuticals, Inc.
Leadership changes · SMNR · SEC Form 8-K, Item 5.02

Leadership changes at Semnur Pharmaceuticals, Inc. (2026)

Before you join, sell to or invest in Semnur Pharmaceuticals, Inc.

MentionFox check on Semnur Pharmaceuticals, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/semnur-pharmaceuticals

Check Semnur Pharmaceuticals, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Semnur Pharmaceuticals, Inc.?

Who joined and who left Semnur Pharmaceuticals, Inc. (SMNR)? 2 appointments and 1 departure reported on 2026-03-17, each cited to the company's own filing.

Henry Ji was named Chief Executive Officer of Semnur Pharmaceuticals, Inc., succeeding Jaisim Shah. As of November 14, 2026, Semnur Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 17, 2026, naming 2 appointments and 1 departure (Form 8-K, March 17, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Scilex Holding Company also filed stake reports on 2 other companies ↓

Sell to companies like Semnur Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · In / out: Out · Person: Jaisim Shah · Role: Chief Executive Officer · Effective: 2026-03-13 · 8-K, 2026-03-17
  • · In / out: In · Person: Henry Ji · Role: Chief Executive Officer · 8-K, 2026-03-17
  • · In / out: In · Person: Stephen Ma · Role: Chief Operating Officer · Effective: 2026-03-17 · 8-K, 2026-03-17
Changes3
In (appointed)2
Out (departing)1
Latest filing2026-03-17

Semnur Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-17. It names 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Semnur Pharmaceuticals, Inc. files it.

Also on the record for Semnur Pharmaceuticals, Inc.

DateRecordFigureOur pageSource
June 26, 2026Stake report, Schedule 13D/A, by Scilex Holding Company78.85% of the class5%+ stakesSource
October 14, 2025Stake report, Schedule 13D/A, by Scilex Holding Company82.07% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by Meteora Capital, LLC—5%+ stakesSource
August 12, 2025Stake report, Schedule 13G/A, by TD SECURITIES (USA) LLC—5%+ stakesSource

Selling to them or working with them? See who runs Semnur Pharmaceuticals, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Semnur Pharmaceuticals, Inc. and the records around it.

Semnur Pharmaceuticals, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Semnur Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Semnur Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Semnur Pharmaceuticals, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    5 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-17OutChief Executive Officer2026-03-138-K, 2026-03-17
2026-03-17InChief Executive Officer8-K, 2026-03-17
2026-03-17InChief Operating Officer2026-03-178-K, 2026-03-17

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads Semnur Pharmaceuticals, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Semnur Pharmaceuticals, Inc.?

New leaders reset buying decisions — get the Full Report on Semnur Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Semnur Pharmaceuticals, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Executive Officer at Semnur Pharmaceuticals, Inc., with the record behind each one.

Find candidates like Chief Executive Officer at Semnur Pharmaceuticals, Inc.

Every change, in the filing's words

Filed 2026-03-17 · 8-K

Departing: Jaisim Shah, Chief Executive Officer, effective 2026-03-13

Departure of Chief Executive Officer and President; Decrease in Size of Board On March 13, 2026, Jaisim Shah, Chief Executive Officer and President of Semnur Pharmaceuticals, Inc. (the "Company"), notified the Company's board of directors (the "Board") that he is retiring and thus resigning from his positions as Chief Executive Officer and President, and as a director of the Company, and will separate from employment effective as of March 13, 2026 (the "Effective Time").

Appointed: Henry Ji, Chief Executive Officer

Appointment of Chief Executive Officer and President In connection with Mr. Shah's departure, the Board appointed Henry Ji, Ph.D., age 61, as the Company's Chief Executive Officer and President effective as of the Effective Time.

Appointed: Stephen Ma, Chief Operating Officer, effective 2026-03-17

Appointment of Chief Operating Officer In connection with Mr. Shah's departure, the Board also appointed Stephen Ma, age 53, as the Company's Chief Operating Officer, with such appointment effective as of March 17, 2026.

Also stated in this filing

  • As a result of Mr. Shah's resignation, the Board has decreased the size of the Board from six directors to five directors as of immediately following the Effective Time.
  • In connection with Mr. Shah's departure, the Company and Mr. Shah have entered into a separation agreement, effective as of March 13, 2026 (the "Separation Agreement"), pursuant to which Mr. Shah will receive six months of continued payment of his base salary (at a rate of $1,250,000 per year) and will be given a 90-day extension of the post-termination exercise period under the applicable equity plan to exercise any of his vested stock options pursuant to the award agreements for such options.
  • Also, pursuant to the Separation Agreement, Mr. Shah's prior employment agreement dated September 22, 2025 was terminated.
  • The Separation Agreement also includes a standard general release of all claims.
  • Dr. Ji has served as the Company's Executive Chairperson and a member of the Board since September 2025 and previously served as Semnur's Treasurer and Secretary and a board member since its inception in 2013.
  • Dr. Ji has served as Executive Chairperson and a board member of Scilex Holding Company (Nasdaq: SCLX) ("Scilex") since September 2023, as Scilex's President and Chief Executive Officer since August 2025, and previously served as Scilex's Executive Chairperson and board member from March 2019 to August 2023.

Tools for this story

Each opens in a new tab, filled in for Semnur Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/semnur-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Semnur Pharmaceuticals, Inc. names Henry Ji CEO (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/semnur-pharmaceuticals